Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Tendyne
December 07, 2016
Neovasc soars as mitral valves head to Europe
October 09, 2015
Boston arrives late to the mitral valve party
September 03, 2015
Interview – Boston’s long road to recovery
September 03, 2015
Mitralmania continues as HeartWare buys Valtech
September 02, 2015
Interview – No St. Jude deal, but Abbott could still buy big
August 26, 2015
Medtronic enters mitral valve race with obscure $400m buy
July 31, 2015
Mitral valve space heats up with Abbott deals
July 13, 2015
Edwards’ $350m CardiAQ buy ups mitral valve stakes
May 20, 2015
Edwards valve stumble makes Tiara sparkle
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
September 11, 2020
Esmo 2020 preview – late-breaking immunotherapy
September 11, 2020
Esmo 2020 preview – a kidney cancer showdown gets star billing
September 30, 2020
More biotechs test the third way to market
August 27, 2020
Abbott rides to the rescue with $5 Covid-19 test
September 16, 2020
Are the stars waning for Pfizer’s haemophilia A gene therapy?
